Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Conclusion: [89Zr]Zr-DFO- and Cy5-daratumumab demonstrated superb binding to CD38+ human MM cells and significantly low binding to CD38low cells. Daratumumab bioconjugates are being evaluated for image-guided delivery of therapeutic radionuclides.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Ghai, A., Maji, D., Cho, N., Chanswangphuwana, C., Rettig, M., Shen, D., DiPersio, J., Akers, W., Dehdashti, F., Achilefu, S., Vij, R., Shokeen, M. Tags: Basic Source Type: research